News

TB kills 1.6m people annually - the world’s deadliest infectious disease. The Market-Driven, Value-Based Advance Commitment (MVAC), creates and guarantees a market for better TB treatment. The final “blueprint” has four pillars: HTA to inform countries’ value-based purchase commitments; commitment guarantees underwritten by a development bank; industrial policy alignment; and a governance structure credible to MIC payers and industry.

Why might differences arise between child and adult QALYs? In the UK, NICE’s science policy and research team is reviewing NICE’s recommendations on child utilities and QALYs. In Australia, the Medical Research Future Fund has announced it will fund research for the PBAC on the topic. This blog sets out a conceptual framework addressing five key issues in measuring and valuing children’s health as compared to that of adults.

This OHE Research Paper describes a study in which four stated preference methods for anchoring EQ-5D-Y values were compared: visual analogue scale, discrete choice experiment (with a duration attribute), lag-time time trade-off, and the recently developed ‘location-of-dead’ element of the personal utility function (PUF) approach.

In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference to the challenges of HTA in the UK. A failure to consistently consider all ultra-rare disease medicines under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions.

Pages